MedscapeJune 6, 2026
Petrelintide Tolerability Could Improve on GLP-1 Challenges
Reported by Medscape. Read the original →
What the story says
The headline suggests that petrelintide may have better tolerability compared to challenges associated with GLP-1. However, no additional details or context are provided in the description.
Summarised by a model from Medscape's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
PetrelintideA · Human clinical
- Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial.Human · RCT · 2026
- Initial HIV Therapy for Adults and Treatment-Associated Weight Gain: The Opti-DOR Randomized Clinical Trial.Human · 2026
- Petrelintide and the evolving role of amylin agonism in obesity.review · 2026
GLP-1 and incretin therapiesclass
14 compounds tracked · 344 studies on file · 150 in humans
What the headline doesn't tell you
- Petrelintide has 3 studies on file, 2 of them in humans, the newest published 2026.
- This story is about a class — GLP-1 and incretin therapies — rather than one compound. We track 14 compounds in it, holding 344 studies between them, 150 in humans.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.